On June 2, 2025 , the FDA (Food & Drug Administration) launched Elsa , an IAG-based assistant designed to accelerate the scientific review process for drugs .
What is Elsa doing?
Elsa assists reviewers, researchers, and scientists in key tasks:
- Clinical data summaries : consolidates protocols, adverse event reports and comparisons.
- Code generation : for handling regulatory databases.
- Identification of inspection priorities : helps to define which requests warrant more urgent examination .
The system is already backed by AWS GovCloud, which ensures that information does not leave the government's secure environment .
Real impact
With traditional review times of 6–10 months, Elsa streamlines essential processes, accelerating key regulatory stages. It is estimated to facilitate thousands of medical approvals in less time and with greater accuracy. The rollout phase concludes on June 30, 2025 , following a successful pilot .
Opportunities and challenges
Advantages :
- Unprecedented efficiency in regulatory agencies.
- Data security support when operating within GovCloud.
- Potential to replicate the model in other global agencies.
Challenges :
- Ethical dilemmas about automating healthcare decisions.
- Need for training and continuous system auditing.
- Cultural adaptation within bureaucratic institutions.
Beyond the FDA
It is anticipated that other entities, such as the EMA (European Union) or ICMR (India), will begin evaluating similar solutions. Elsa is presented as a success story that could propel IAG into critically regulated procedures.
👉 We recommend reading our article: Beyond “Chinchilla”: Are we entering the era of AI reasoning?